Exploring Lung Function Decline in IPF and PPF at the ERS Congress
Impact of Lung Function Decline in IPF and PPF
The ERS Congress revealed important updates on idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), focusing on the role of lung function decline in patient outcomes. This report underscores the physiological implications of these diseases and the effectiveness of nintedanib in treatment.
FVC Decline in Patients with IPF and PPF
- Claudia Valenzuela, MD, presented findings on baseline forced vital capacity (FVC) decline from the INPULSIS and INBUILD trials.
- Results indicated a reduction in FVC decline by 49% in IPF and 57% in PPF patients treated with nintedanib compared to a placebo.
- Patients exhibited significantly impaired lung function compared to healthy individuals, with mean baseline FVC values markedly lower.
Lung Function Decline and Mortality Risk
Another significant presentation by Divya Patel, DO, MBA, emphasized the relationship between lung function decline and increased mortality risks in IPF patients. Analysis from the IPF-PRO Registry demonstrated that even minor declines in lung function were associated with heightened mortality or transplant risk.
- Relative declines of –3.3% in FVC and –11.2% in DLco reflected critical prognostic indicators.
- Risk assessments showed a direct correlation between FVC and DLco threshold declines and mortality risk.
These compelling findings reinforce the necessity for vigilant monitoring of lung function in patients with IPF and PPF, showcasing the clinical relevance of nintedanib treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.